In this roundtable discussion, Dr. John Lasala of Washington University in St. Louis interviews Dr. Bill O’Neill (Henry Ford Hospital, Detroit, MI), Dr. Bill Lombardi (University of Washington, Seattle, WA), and Dr. Jeff Moses (Columbia University, New York, NY) on the current data regarding high-risk patients undergoing Protected PCI. During this interview, Dr. Moses provides … Continue reading “Protected PCI: Current Data and Best Practices in High-Risk Patients”
Dr. John Lasala presents the clinical guidelines for use of hemodynamic support. He outlines the role of hemodynamic support with Impella 2.5 and Impella CP heart pumps in high-risk PCI settings. He also presents an equation and algorithm for clinical decision-making as well as a definition for the high-risk patient. Subscribe, or join the conversation … Continue reading “Protected PCI Clinical Guidelines and Algorithms”
Drs. John Lasala, Bill O’Neill, Jeff Moses, and Bill Lombardi explain the benefit of Impella support during Protected PCI for revascularization.
Impella 2.5 and Impella CP are now approved by the FDA as safe and effective for use during high-risk PCI procedures. Learn more about the data and the clinical guidelines that support the approval. Additionally, learn how to identify patients who can benefit from Protected PCI and revascularization. Tune into this valuable conversation! Chapters include:
Maintaining Hemodynamic stability during high-risk PCI
Complete Revascularization is the Therapeutic Goal
Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardiogenic shock so we asked Dr. John Lasala to describe his experiences with Impella while treating shock patients. (Tweet This)
A live case transmission presented at the American College of Cardiology 2016 Scientific Session on April 3 turned into a lesson on patience, as well as the necessity for hemodynamic support.Broadcasting from Barnes-Jewish Hospital in St. Louis, John M. Lasala, MD, and Jasvindar Singh, MD, tackled the case of an 84-year-old man with severe multivessel disease featuring a 90% calcified mid RCA and 80% tandem calcified proximal and mid LAD stenoses. Continue readingImpella Buys Time for Complex Procedures: ACC.2016 Live Case
The SCAI 2015 Fall Fellows course entitled “Protected PCI: Treating the Complex Higher-Risk Indicated Patients (CHIP)” this past weekend in Las Vegas, over 120 fellows from 25 countries. The course focused on the use of hemodynamic support for high-risk PCI patients and the technical and cognitive skills required for cardiology fellows to develop their own Protected PCI program once they complete their Interventional Cardiology fellowship.The course was run by faculty renowned for their fellowship programs and included didactic sessions, case presentations, and hands-on simulator demonstrations.Continue readingSCAI 2015 Fall Fellows Course Discusses Hemodynamic Support for High-Risk PCI Patients
In the video below, Dr. John Lasala from Washington University, St. Louis, Missouri, hosts a roundtable discussion on Protected PCI with Dr. Bill Lombardi from the University of Washington, Seattle, Washington, Dr. Jeff Moses, Columbia University, New York, NY, and Dr. Bill O’Neill, Henry Ford Hospital, Detroit, Michigan.Continue readingRoundtable Discusses Protected PCI for High-Risk Patients
Protected percutaneous coronary intervention (PCI) with the Impella® 2.5 heart pump was the focus of the talk by Dr. John Lasala, Director of Interventional Cardiology at the Washington University School of Medicine in St. Louis, Missouri. His talk was titled “Preparing for a Growing Population in the Cath Lab" and was presented at the 26th annual 2015 Scripps Cardiovascular Interventions Conference on Tuesday, October 27, 2015. Dr. Lasala was a featured speaker in the preconference session called “A New Procedure in the Cath Lab: Protected PCI Treating Complex and Higher-Risk Indicated Patients (CHIP).”Dr. Lasala began by describing the Impella 2.5, which is the only hemodynamic support device proven safe and effective for use in treating elective and urgent high-risk PCI patients, and which may reduce peri and post-procedural adverse events. The Impella heart pump is designed to protect the patient hemodynamically during a high-risk PCI procedure.Continue readingDr. John Lasala Discusses Benefits of Protected PCI at Scripps 2015
There is a growing need in the cath lab to treat more high risk patients, per the CHIP initiative. Dr. Ajay Kirtane, Dr. John Lasala, Dr. Jeff Popma and Dr. Jeff Moses discuss. Subscribe or join the conversation by following us on Twitter: @ProtectedPCI IMP-820-16
Subscribe to the Digital Community
Receive weekly updates including case review videos, tips and tricks, specialists opinions, and resources and downloads regarding Protected PCI and Cardiogenic Shock.